In a dramatic reversal, Britain has secured a groundbreaking UK-US zero-tariff deal on pharmaceuticals, compelling US President Donald Trump to back down from his bold trade threats. The agreement, unveiled on 1 December 2025, underscores how strategic negotiations forced Washington to blink on imposing severe Section 232 tariffs.
Against the backdrop of escalating NHS drug prices and a new transatlantic trade pact, this rapid tariff reversal reshapes pharmaceutical pricing and strengthens health trade relations between the allies.
